

อุบัติการณ์ของผลบวกในการตรวจกรองก่อนคลอดเชื้อซิฟิลิสครั้งที่สองที่โรงพยาบาลศรีนครินทร์ มหาวิทยาลัยขอนแก่น

ประนอม บุพศิริ, สรายุทธ ไชยลิทธี

ภาควิชาสุสัติศาสตร์และนรีเวชวิทยาคณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น

Incidence of Positive VDRL in the Second Antenatal Screening for Syphilis at Srinagarind Hospital, Khon Kaen University

Pranom Buppasiri, Sarayoot Chaisitt

Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University

หลักการและวัตถุประสงค์: เพื่อหาอุบัติการณ์ของผลบวกในการตรวจกรองก่อนคลอดเชื้อซิฟิลิสครั้งที่สอง ในสตีตั้งครรภ์ที่มีผลคลอดที่โรงพยาบาลศรีนครินทร์

วิธีการศึกษา: เป็นการศึกษาเชิงพรรณนาแบบข้อมูลหลังในสตีตั้งครรภ์ที่มีผลคลอดที่โรงพยาบาลศรีนครินทร์ คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่นทั้งหมด ในระหว่างวันที่ 1 มกราคม พ.ศ. 2546 ถึงวันที่ 31 ธันวาคม พ.ศ. 2550 และมีผลการตรวจกรองก่อนคลอดเชื้อซิฟิลิสด้วยวิธี Venereal Disease Research Laboratory (VDRL) สองครั้ง โดยเก็บรวบรวมข้อมูลของสตีตั้งครรภ์ที่มีผลคลอด ทารกและผลของการคลอดที่มีผลการตรวจคัดกรองซิฟิลิสด้วยวิธี VDRL ในสตีตั้งครรภ์ครั้งที่สองเป็นบวก

ผลการศึกษา: จากการศึกษาพบว่า สตีตั้งครรภ์ที่มีผลคลอดที่โรงพยาบาลศรีนครินทร์ทั้งหมด 13,527 ราย ไม่มีข้อมูลการตรวจหรือผล VDRL 627 ราย ดังนั้นจึงมีจำนวนสตีตั้งครรภ์ที่มีผลคลอดที่มีผลการตรวจด้วยวิธีซิฟิลิส 2 ครั้งมีจำนวน 12,652 ราย มีสตีตั้งครรภ์ที่มีผลการตรวจด้วยวิธีซิฟิลิส 2 ครั้งมีจำนวน 12,652 ราย มีสตีตั้งครรภ์ที่มีผลการตรวจด้วยวิธีซิฟิลิสให้ผลบวกครั้งเดียวเท่านั้น 45 ราย โดยเป็นการตรวจครั้งแรก 32 ราย ครั้งที่สอง 13 ราย ที่มีการตรวจครั้งแรกและครั้งที่สองให้ผลบวกทั้ง 2 ครั้ง 32 ราย ดังนั้นจึงมีสตีตั้งครรภ์ที่มีผลการตรวจด้วยวิธีซิฟิลิสให้ผลบวกครั้งแรก 32 ราย ดังนั้นจึงมีสตีตั้งครรภ์ที่มีผลการตรวจด้วยวิธีซิฟิลิสให้ผลบวกครั้งแรกและครั้งที่สองเป็นบวก 13 ราย คิดเป็นร้อยละ 0.1 (13 ใน 12,620) ซึ่งในจำนวนทั้ง 13 รายนี้ มีการตรวจยืนยันการติดเชื้อจริง ร้อยละ 0.02 (2 ใน 12,620)

สรุป: อุบัติการณ์ของผลบวกในการตรวจคัดกรองก่อนคลอดเชื้อซิฟิลิสครั้งที่สองเป็นบวกมีค่าค่อนข้างต่ำ หากตรวจครั้งแรก

Background and Objective: To determine the incidence of positive result (reactive VDRL) in the second antenatal screening for syphilis in pregnant women who delivered at Srinagarind Hospital.

Methods: A retrospective descriptive study was conducted at Srinagarind Hospital, Khon Kaen University. All of the mothers had two antenatal Venereal Disease Research Laboratory (VDRL) screening tests and delivered babies during January 1, 2003 - December 31, 2007 were included in this study. Result of VDRL test, maternal and neonatal outcomes were analyzed.

Results: In the total number of 13,527 pregnant women delivered at Srinagarind Hospital during the study period, 627 cases had no data of VDRL screening. Only 12,900 medical records were analyzed and 12,652 pregnant women had two VDRL screening tests. Forty-five cases were positive for VDRL screening either in first or second screening. Thirty-two in 45 cases were positive for the first VDRL screening and, therefore, were excluded from this study. The 12,620 pregnant women who had negative VDRL screening in the first time were recruited. The incidence of positive results in the second antenatal syphilis infection screening was 0.1% (13 in 12,620 cases). In addition, 0.02% (2 in 12,620 cases) had positive confirmatory Treponema pallidum Hemagglutination Antibody (TPHA) test.

Conclusion: Incidence of positive results in the second antenatal screening for syphilis who had negative results

ให้ผลลบ

คำสำคัญ: การตรวจกรองก่อนคลอด, ซิฟิลิสในการตั้งครรภ์

in the first antenatal screening was very low.

Key words: VDRL, syphilis in pregnancy, TPHA test

ศรีนารินทร์เวชสาร 2552; 24(4): 292-5 • Srinagarind Med J 2009; 24(4): 292-5

Introduction

Syphilis is a sexually transmitted disease caused by *Treponema pallidum*. The bacteria could be transmitted from pregnant woman to her fetus. In untreated cases, it is a risk for miscarriage, preterm labor, fetal death in utero and congenital syphilis¹. Most of syphilis in pregnancy does not show any signs or symptoms². Serological test is a mainstay technique to detect syphilis during pregnancy. VDRL (Venereal Disease Research Laboratory) or RPR (Rapid Plasma Reagins) are used but they are non-specific test. FTA-ABS (Fluorescent Treponemal Antibody Absorption), TPHA (Treponemal pallidum Hemagglutination Antibody) or TP-PA (Treponema pallidum Particle Agglutination) are used to confirm in case of positive screening test³. In our routine antepartum screening, blood for VRDL is drawn in two occasions during pregnancy, first time at antenatal care clinic visit and the second time at the third trimester of pregnancy. There was inconsistent evidence regarding benefit of the second syphilis screening in case of negative result (non-reactive VDRL) in the first screening⁴⁻⁶.

Objective

To determine the incidence of positive results (reactive VDRL) in the second antenatal screening for syphilis in pregnant women who delivered at Srinagarind Hospital.

Methods

We retrospectively reviewed and analysed 13,527 medical records of pregnant women who delivered at Srinagarind Hospital, Khon Kaen University between January 1, 2003- December 31, 2007. Inclusion criteria were all pregnant women who had antenatal VDRL screening in 2 occasions. The exclusion criteria were pregnant women who had reactive VDRL in first antenatal screening or had

only one occasion of VDRL testing. We recorded the data pertaining to demographic data of the included parturient, results of VDRL, mean age, gestational age, birth weight, complication of pregnancy and APGAR score. Sample size calculation was based on the assumption that the prevalence of reactive VDRL during pregnancy was 0.9%⁵, then we needed at least 10,575 pregnant women for this study. The data was analyzed by using SPSS for window version 11.5. Descriptive statistics were used to determine incidence of positive results in the second antenatal syphilis screening, mean age of parturient, mean gestation age of parturient and mean birth weight of neonates. This study was approved by the Ethics Committee of Faculty of Medicine, Khon Kaen University (HE 510716).

Results

There were 13,527 pregnant women delivered at Srinagarind Hospital during study period. Antenatal VDRL profile was missed during antenatal care in 4.6 % (627 cases). The total number of 12,652 from 12,900 women have had two occasions VDRL screening. There were 45 cases showed reactive VDRL (32 cases had positive VDRL in the first antenatal screening test, and 13 had reactive VDRL in the second antenatal screening test). The incidence of positive results either in the first or the second antenatal screening was 0.39 % (45 in 12,900). For the remaining 12,620 pregnant women, 13 cases had positive VDRL in the second antenatal screening test. Therefore the incidence of positive results in the second VDRL screening out of the non-reactive VDRL in the first screening was 0.1% (13 in 12,620 cases). Mean age, mean gestational age and mean birth weight of the parturients in non-reactive VDRL group and reactive in the second VDRL screening group were not statistical significant different (Table 1).

Table 1 Comparison between non-reactive VDRL in two occasions and reactive VDRL in the second screening parturients

| | Non-reactive VDRL in 2 occasions group (n=12,607) | | | Reactive VDRL in the second screening group (n= 13) | | | Total (n=12,620) |
|----------------------|---|----------------------|------------------|---|--|----------------------------------|---------------------|
| | Range | | Mean | Range | | Mean | |
| | Age (yrs) | GA (wks) at delivery | Birth weight (g) | GA= gestational age | | NS= non-statistical significance | |
| Age (yrs) | 14-46 | | 28.04 | 16-36 | | 26.63 | NS |
| GA (wks) at delivery | 32-45 | | 38.46 | 34-41 | | 38.53 | NS |
| Birth weight (g) | 785-5,940 | | 3,100.43 | 2,210-3,880 | | 3,063.80 | NS |

GA= gestational age

NS= non-statistical significance

Table 2 Characteristics of pregnant women who reactive second VDRL screening

| Case No. | Age (yrs) | Gravida | No. of ANC | GA at first screening (wks) | GA at second screening (wks) | Titer | TPHA | Rx | Hb | GA at delivery (wks) | Mode | Sex | BW (g) | APGAR score | APGAR score | Complications |
|----------|-----------|---------|------------|-----------------------------|------------------------------|-----------------|----------|-----|------|----------------------|------|-----|--------|-------------|-------------|---------------------|
| | | | | | | | | | | | | | | at 1 min | at 5 min | |
| 1 | 20 | 2 | 7 | 12 | 34 | 1:1 | Negative | No | 11.8 | 38 | NL | M | 2,650 | 9 | 10 | |
| 2 | 30 | 3 | 11 | 18 | 33 | 1:2 | Negative | No | 11.7 | 40 | NL | F | 3,100 | 8 | 10 | |
| 3 | 31 | 1 | 10 | 10 | 33 | 1:1 | Negative | No | 12.7 | 37 | C/S | M | 2,960 | 9 | 10 | Breech presentation |
| 4 | 28 | 2 | 15 | 8 | 31 | Weakly reactive | Negative | No | 11.8 | 40 | NL | F | 2,800 | 9 | 10 | SLE, Rh negative |
| 5 | 25 | 3 | 12 | 7 | 32 | Weakly reactive | Positive | Yes | 12 | 40 | NL | M | 3,220 | 9 | 10 | Uterine atony |
| 6 | 26 | 2 | 10 | 15 | 32 | Weakly reactive | Negative | No | 11.4 | 38 | NL | M | 3,720 | 8 | 10 | |
| 7 | 34 | 3 | 14 | 7 | 33 | 1:1 | Negative | No | 13.5 | 41 | NL | M | 3,880 | 6 | 10 | Oligo hydramnios |
| 8 | 36 | 2 | 12 | 8 | 31 | Weakly reactive | Positive | No | 13.4 | 34 | NL | F | 2,210 | 9 | 10 | Preterm, GDM2 |
| 9 | 20 | 1 | 8 | 25 | 32 | 1:2 | Negative | No | 9.3 | 38 | NL | F | 3,000 | 9 | 10 | |
| 10 | 28 | 1 | 15 | 5 | 32 | 1:1 | Negative | No | 10.8 | 40 | NL | F | 3,320 | 7 | 10 | |
| 11 | 33 | 3 | 6 | 9 | 32 | Weakly reactive | Negative | No | 12 | 39 | NL | M | 2,800 | 10 | 10 | |
| 12 | 19 | 2 | 9 | 15 | 32 | 1:1 | Negative | No | 11.6 | 38 | NL | M | 3,530 | 8 | 10 | |
| 13 | 16 | 1 | 11 | 13 | 32 | 1:1 | Negative | No | 10.3 | 38 | NL | F | 2,640 | 10 | 10 | |

ANC = antenatal care, GA = gestational age, Rx = treatment, Hb = hemoglobin, BW = body weight

Characteristics of the 13 parturients with reactive VDRL in the second screening were shown in table 2. In most cases they were multiparous and term pregnancy. Mean hemoglobin was 11.64 g/dl. Anti HIV, HbsAg were negative in all cases. Titer of reactive VDRL was quite low.

The confirmatory test was done in all 13 cases by using TPHA. 15.4 % of cases (2 in 13 cases) confirmed syphilis infection. Finally, the incidence of syphilis infection during pregnancy after the non-reactive VDRL at the first screening was 0.02% (2 in 12,620 cases). The false positive rate of

reactive VDRL in this study was 84.6 %. One of the two infected cases was not treated and resulted in preterm labor. After extensive data investigation, we could not find any data. Postpartum hemorrhage due to uterine atony occurred in one infected cases that treated with benzathine penicillin.

Discussion

The incidence of positive results in the second antenatal syphilis infection in the group of non-reactive VDRL in first screening test was 0.1%. The incidence of true syphilis

infection during pregnancy after non-reactive test at the first screening was only 0.02%. Our study showed lower incidence of syphilis infection during pregnancy than that was reported in previous studies^{1,5}. The reasons may be the success of the campaign by private and government sectors to protect sexually transmitted disease especially HIV infection. Sexuality also decreased during pregnancy period⁷. In this study we could not identify the risk factors of syphilis infection such as history of still birth, younger age as stated in previous studies⁵. This may attribute to the low incidence of the reactive test in the second VDRL screening.

One untreated case developed preterm labor. This might be the direct effect of syphilis infection as mention in previous study¹. But the other case, although syphilis was treated, uterine atony still developed. The real cause of uterine atony was unknown. It might not be the effect of syphilis infection but an as over distention or placomegaly because the fetal birth weight and placental weight were within normal range.

In this study the false positive rate of reactive VDRL was very high when compared with other studies^{8,9}. Pregnancy itself can also cause false positive VDRL¹⁰. The reason in our circumstance may be a very low incidence of syphilis infection in our area. In addition, in cases of questionable VDRL titer, the results were all reported as reactive for further confirmatory test.

The incidence of syphilis infection in the second syphilis screening in case of non-reactive results in the first screening was very low in our study. We totally agree with the routine screening of the first VDRL test. But cost-benefit of routine screening of the second VDRL test in pregnant women who had non-reactive VDRL in the first screening should be reconsidered especially in context of very low incidence of syphilis infection. The VDRL test fee in our setting is 50 baht per case. However, syphilis is treatable disease and congenital syphilis can be prevented in the proper care of pregnant women¹¹. Therefore the second VDRL screening test is still of advantage to some extent especially to the case of high risk of syphilis infection or requested by pregnant women after we provide them with adequate information.

The limitation of this study was a retrospective study. Incomplete data was the major problem. In addition, this was the tertiary hospital-based data that might not represent the real situation of syphilis infection in community. Further

research in community, rather than tertiary hospital would provide a real incidence of the non-reactive VDRL test at the secondary screening. In addition, a cost-benefit study would provide valuable findings on this issue and then a strong recommendation on the second antenatal VDRL test could be made and generalized.

References

1. Barbara M, Sreelatha U. Screening and treatment for sexually transmitted infections in pregnancy. *Am Fam Physic* 2007; 76:265-70.
2. Marangani A, Moronia A, Tridapalli E, Capretti MG, Farneti G, Faldella G, et al. Antenatal syphilis serology in pregnant women and follow-up of their infants in northern Italy. *Clin Microbiol Infect* 2008; 14:1065-8.
3. Wiwanitkit V. Screening for syphilis in pregnancy: which is the proper method? *Arch Gynecol Obstet* 2007; 276: 629-31.
4. Goh BT, Thornton AC. Antenatal screening for syphilis. *Sex Transm Infect* 2007; 83: 345-6.
5. Lumbiganon P, Piaggio G, Villar J, Pinol A, Bakketeg L, Bergsjo P, et al. The epidemiology of syphilis in pregnancy. *Int J STD AIDS* 2002; 13:486-94.
6. Kiss H, Widhalm A, Geusau A, Husslein P. Universal antenatal screening for syphilis: is it still justified economically? A 10-year retrospective analysis. *Eur J Obstet Gynecol Reprod Biol* 2004; 112: 24-8.
7. Von Sydow K. Sexuality during pregnancy and after childbirth: a metacontent analysis of 59 studies. *J Psychosom Res* 1999; 47:27-49.
8. Iris M, Volker B, Hans-Jochen H, Erich S, Christoph S, Matthias F, et.al. Is serological testing a reliable tool in laboratory diagnosis of Syphilis? Meta-analysis of eight external quality control surveys performed by the German infection serology proficiency testing program. *J Clin Microbiol* 2006; 44:1335-41.
9. Smikle MF, James OB, Prabhakar P. Biological false positive serological tests for syphilis in Jamaican population. *Genitourin Med* 1990; 66:76-8.
10. Nadwadi R, Evans DT. Are you sure it's syphilis? A review of false positive serology. *Int J STD AIDS* 1995; 6:241-8.
11. Peeling RW, YE H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an over review. *Bull World Health Organ* 2004; 82:439-46.

